清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract 1533: IMGC936, a first-in-class ADAM9-targeting antibody-drug conjugate, demonstrates promising anti-tumor activity

转移 抗体-药物偶联物 癌症 人源化抗体 血管生成 癌症研究 体内 抗体 医学 生物 单克隆抗体 免疫学 内科学 生物技术
作者
Stuart W. Hicks,Deryk T. Loo,Kerstin W. Sinkevicius,Juniper A. Scribner,Bhaswati Barat,Nicholas C. Yoder,Christopher W. Espelin,Marian Themeles,Francine Chen,Jacquelynn Lucas,Jennifer G. Brown,Bahar Matin,Megan E. Fuller,Jenny Lee,Paulin L. Salomon,Juliet A. Costoplus,Sadiqa Yancey,Gundo Diedrich,Sergey N. Gorlatov,Thomas Son
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:79 (13_Supplement): 1533-1533 被引量:4
标识
DOI:10.1158/1538-7445.am2019-1533
摘要

Abstract Dysregulation of ADAM9, a member of the ADAM (a disintegrin and metalloproteinase) family of proteases, has been implicated in tumor progression and metastasis, as well as pathological neovascularization. ADAM9 overexpression correlates with poor prognosis in multiple cancers. We have shown that ADAM9 is overexpressed in multiple solid tumor indications and that anti-ADAM9 antibodies are efficiently internalized and degraded by tumor cell lines making ADAM9 an attractive target for antibody-drug conjugate (ADC) development. Here, we describe IMGC936, the first ADAM9-targeting ADC to enter preclinical development. IMGC936 is comprised of a high-affinity humanized antibody site-specifically conjugated to DM21, a next-generation linker-payload that combines a maytansinoid microtubule-disrupting payload with a stable peptide linker at a drug-antibody ratio of two. To maximize the potential for IMGC936 activity, the M252Y/S254T/T256E (YTE) mutation was introduced into the CH2 domain of the antibody to increase in vivo plasma half-life and exposure. In vitro studies demonstrated targeted cytotoxicity of IMGC936 across a panel of ADAM9-positve tumor cell lines with activity at least 2 logs greater than a non-targeting conjugate. Consistent with the in vitroactivity, an anti-ADAM9-DM21 conjugate displayed compelling anti-tumor activity in multiple xenograft models representing non-small cell lung, gastric and colorectal cancers. For example, in the EBC-1 non-small cell lung cancer subcutaneous xenograft model with only moderate ADAM9 expression (H-score of 130), anti-ADAM9-DM21 not only induced tumor growth delay but produced complete and durable remissions in 6/6 mice following a single intravenous dose of 8.6 mg Ab/kg (100 ug DM21/kg). IMGC936 demonstrated a favorable pharmacokinetic profile with good conjugate stability in non-human primates. Importantly, IMGC936 was well-tolerated following repeat dosing in cynomolgus monkeys with no ADAM9 target-related toxicities identified at doses exceeding the levels required for anti-tumor activity in murine xenograft models. Based on the totality of the preclinical data, IMGC936 represents a promising therapeutic candidate to target a wide range of ADAM9-expressing tumors. Citation Format: Stuart Hicks, Deryk Loo, Kerstin Sinkevicius, Juniper Scribner, Bhaswati Barat, Nicholas Yoder, Christopher Espelin, Marian Themeles, Francine Chen, Jacquelynn Lucas, Jennifer Brown, Bahar Matin, Megan Fuller, Jenny Lee, Paulin Salomon, Juliet Costoplus, Sadiqa Yancey, Gundo Diedrich, Sergey Gorlatov, Thomas Son, Michael Chiechi, Pam Li, Michael Spliedt, Valentina Ciccarone, Jeff Hooley, Nadia Gantt, James Tamura, Kerry Donahue, Paul Moore, Syd Johnson, Thomas Chittenden, Richard Gregory, Ezio Bonvini. IMGC936, a first-in-class ADAM9-targeting antibody-drug conjugate, demonstrates promising anti-tumor activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1533.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
HelloBOB完成签到 ,获得积分10
刚刚
6秒前
俭朴竺完成签到,获得积分10
12秒前
liangyao完成签到,获得积分20
14秒前
Tardes关注了科研通微信公众号
20秒前
22秒前
朴实惜寒完成签到,获得积分10
30秒前
11完成签到 ,获得积分10
30秒前
32秒前
king完成签到 ,获得积分10
37秒前
wsj完成签到 ,获得积分10
38秒前
Tardes发布了新的文献求助10
39秒前
ss完成签到,获得积分10
42秒前
甜美的梦芝完成签到,获得积分10
44秒前
西瓜柠檬可乐完成签到 ,获得积分10
59秒前
李煜琛完成签到 ,获得积分10
1分钟前
悦耳的竺完成签到 ,获得积分10
1分钟前
搜集达人的应助被冲冲冲采纳,获得10
1分钟前
大力的安阳完成签到 ,获得积分10
1分钟前
无花果的应助被ZLPY采纳,获得30
1分钟前
1分钟前
1分钟前
刘亚梅完成签到 ,获得积分10
1分钟前
醉熏的小凡完成签到,获得积分10
1分钟前
冲冲冲发布了新的文献求助10
1分钟前
apt完成签到 ,获得积分10
1分钟前
1分钟前
忧伤的白秋完成签到,获得积分10
1分钟前
1分钟前
lx完成签到 ,获得积分10
1分钟前
天天快乐的应助被hilufite采纳,获得10
1分钟前
nhzz2023完成签到 ,获得积分10
1分钟前
和谐如彤完成签到,获得积分10
1分钟前
nanjing01完成签到 ,获得积分10
1分钟前
如泣草芥完成签到,获得积分10
1分钟前
Jessie完成签到,获得积分10
1分钟前
RZH发布了新的文献求助50
2分钟前
hy发布了新的文献求助10
2分钟前
笙歌完成签到 ,获得积分10
2分钟前
点点完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780536
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697